M9466 + FOLFIRI + bevacizumab

M9466 + FOLFIRI + bevacizumab is a combination regimen comprised of the investigational PARP1 inhibitor **M9466**, the chemotherapy regimen **FOLFIRI** (folinic acid, fluorouracil, irinotecan), and the monoclonal antibody **bevacizumab**. In clinical development, this combination is being evaluated for the treatment of **advanced solid tumors** and **metastatic colorectal cancer** that are refractory to or have progressed after standard therapies. M9466 inhibits poly(ADP-ribose) polymerase 1 (PARP1), impairing cancer cell repair mechanisms and potentially synergizing with cytotoxic chemotherapy. FOLFIRI disrupts DNA synthesis (5-FU), enhances 5-FU activity (folinic acid), and inhibits topoisomerase I–mediated DNA replication (irinotecan). Bevacizumab inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF). This regimen is administered intravenously and is currently in clinical trials to determine its safety, maximum tolerated dose, and recommended dose for expansion[2][4].